Harbour Investments’s Citius Pharmaceuticals CTXR Stock Holding History

Harbour Investments’s Portfolio CTXR Stock Details CTXR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-50	Closed	-$39	–	4693
2025 Q4	$39	Buy	+50	New	+$63	﹤0.01%	3797

Other funds holding CTXR

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

AAG

Asset Advisory Group Kinnelon, New Jersey $229M AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Harbour Investments's CTXR Position: Q1 2026 in Review

Harbour Investments sold out of Citius Pharmaceuticals (CTXR) in Q1 2026, closing a stake of 50 shares — an estimated $39 sold.

Harbour Investments first reported a position in CTXR in Q4 2025 and held it in 1 quarter. The position peaked at $39 in Q4 2025. 38 funds tracked by Wall St. Rank hold CTXR as of Q1 2026.

Harbour Investments reported no remaining Citius Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Harbour Investments sold 50 Citius Pharmaceuticals shares in Q1 2026, an estimated $39.
Harbour Investments first reported a position in Citius Pharmaceuticals in Q4 2025 and held it in 1 quarter.
Harbour Investments's Citius Pharmaceuticals position peaked at $39 in Q4 2025.
38 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q1 2026.

Based on Harbour Investments's 13F filing for Q1 2026, filed 15 May 2026.